Can Serum Lactate on Admission to Intensive Care Predict Length of Stay? A Retrospective Analysis of Critically Ill Paediatric Oncology Patients
Kann Serumlaktat bei Aufnahme auf die Intensivstation die Aufenthaltsdauer vorhersagen? Retrospektive Analyse kritisch kranker pädiatrischer Onkologie-Patient:innen
Journal of Paediatrics and Child Health · 2025-08 · 61 (8) · 1295-1300
DOI: 10.1111/jpc.70110 ↗Auf einen Blick
Bei 633 PICU-Aufnahmen von 426 Kindern war Hyperlaktatämie bei Aufnahme mit längerer PICU-Verweildauer verbunden. Der Zusammenhang zeigte sich nur in der Gruppe mit soliden Tumoren.
Fragestellung
Ist Serumlaktat bei Aufnahme in die PICU mit der Dauer des PICU-Aufenthalts bei pädiatrischen Onkologie-Patient:innen assoziiert?
Methode
Retrospektive Beobachtungsstudie an einem tertiären Kinderkrankenhaus; 2015 bis 2020; multilevel Regression mit Kontrolle demografischer und klinischer Kovariablen.
Ergebnisse
633 PICU-Aufnahmen von 426 Kindern. 197 Aufnahmen mit Hyperlaktatämie, 229 mit normalem Laktat, 207 ohne Messung. Hyperlaktatämie war mit 1,25-fach längerer PICU-LOS assoziiert (95 %-KI 1,04–1,51); nur bei soliden Tumoren.
Einschränkungen
In Sensitivitätsanalysen mit nur gemessenem Laktat war der Effekt reduziert und nicht mehr signifikant.
Schlussfolgerung der Autor:innen
Nach Anpassung an klinische und demografische Kovariablen war erhöhtes Laktat bei PICU-Aufnahme mit der PICU-LOS bei Kindern mit soliden Tumoren assoziiert.
Kernaussagen
- Hyperlaktatämie bei Aufnahme: 1,25-fach längere PICU-LOS
- Zusammenhang nur bei solidem Tumor
- Sensitivitätsanalyse: Effekt nicht mehr signifikant
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Paediatrics and Child Health, online erschienen am 12.06.2025. Verfasst von Megan B Sim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Intensive Care Unit, Queensland Children's Hospital, South Brisbane, Australia. Hauptthemen laut MEDLINE: Intensive Care Units, Pediatric, Length of Stay, Critical Illness, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Intensivpflege
Abstract (Originalsprache)
Introduction
Nearly 40% of hospitalised oncology patients are admitted to the paediatric intensive care unit (PICU). Clinicians utilise serum lactate as a biomarker to guide resuscitation and ongoing management of critically ill children. The significance of raised serum lactate remains unknown in oncology patients. Those who require an admission to the PICU have relatively poorer outcomes compared to those only managed on hospital wards, where there may be an increased tendency to apply additional interventions to normalise lactate. We assessed the association between serum lactate and the length of stay in PICU in paediatric oncology patients. Patients and Methods We conducted a retrospective observational study of patients admitted to the oncology service, who had at least one PICU admission, at a tertiary children's hospital between 2015 and 2020. The outcome was PICU length of stay (LOS). Multilevel regression modelling assessed the association between lactate measured at PICU admission and PICU LOS, controlling for patient demographic and clinical covariates.
Results
There were 633 admissions to PICU from 426 children. Of these 633 admissions, 197 (31.1%) had hyperlactatemia (serum lactate ≥ 2 mmol/L) on admission, 229 (36.2%) had normal lactate levels (< 2 mmol/L) and the remaining 207 (32.7%) did not have lactate measured on admission. Of the 426 patients, 292 (68.5%) were diagnosed with solid tumour, 82 (19.2%) hematologic malignancy, and 52 (12.2%) had received a bone marrow transplant (BMT). The median PICU length of stay was 29 h (interquartile range 21, 68). Hyperlactatemia was associated with an average 1.25‐fold (95% CI [1.04, 1.51]) increase in PICU LOS when we assumed that missing lactate indicated absence of hyperlactatemia. Interaction effects revealed that this association was only present in the solid tumour group. In sensitivity analyses including only admissions with measured lactate, this effect was reduced and no longer significant ( β 1.20, 95% CI [0.99, 1.46]).
Conclusion
After adjusting for clinical and demographic covariates, increased lactate at PICU admission was associated with PICU LOS in paediatric solid tumour patients. While further larger prospective studies are required, serum lactate levels may serve as a predictive biomarker for PICU length of stay in children with solid tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatric Intensive Care Unit, Queensland Children's Hospital, South Brisbane, Australia.
- Paediatric Oncology Services Group, Queensland Children's Hospital, South Brisbane, Australia.
- Children's Intensive Care Research Program, Child Health Research Centre, The University of Queensland, Brisbane, Australia.
ORCID-Profile: Megan B Sim, Trisha Soosay Raj
Zitieren
APA
Sim, M. B., Gilholm, P., Ergetu, E., Raj, T. S., Gibbons, K., & Raman, S. (2025). Can Serum Lactate on Admission to Intensive Care Predict Length of Stay? A Retrospective Analysis of Critically Ill Paediatric Oncology Patients. Journal of Paediatrics and Child Health, 61(8), 1295-1300. https://doi.org/10.1111/jpc.70110
Vancouver
Sim MB, Gilholm P, Ergetu E, Raj TS, Gibbons K, Raman S. Can Serum Lactate on Admission to Intensive Care Predict Length of Stay? A Retrospective Analysis of Critically Ill Paediatric Oncology Patients. Journal of Paediatrics and Child Health. 2025;61(8):1295-1300. doi:10.1111/jpc.70110
BibTeX
@article{Sim2025,
author = {Sim, Megan B and Gilholm, Patricia and Ergetu, Endrias and Raj, Trisha Soosay and Gibbons, Kristen and Raman, Sainath},
title = {Can Serum Lactate on Admission to Intensive Care Predict Length of Stay? A Retrospective Analysis of Critically Ill Paediatric Oncology Patients},
journal = {Journal of Paediatrics and Child Health},
year = {2025},
volume = {61},
number = {8},
pages = {1295--1300},
doi = {10.1111/jpc.70110}
}
EUVIMED